224OPatient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
Friedlander, M L, Moore, K N, Colombo, N, Scambia, G, Kim, B-G, Oaknin, A, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Banerjee, S, Oza, A, González-Martín, A, Aghajanian, C, BradleyVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz426
Date:
November, 2019
File:
PDF, 104 KB
2019
File converter
More search results
More benefits 
